Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Zentalis Pharmaceuticals, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Zentalis Pharmaceuticals, Inc. (ZNTL $3.50), a clinical-stage biotech company focused on developing azenosertib, a small-molecule WEE1 inhibitor, for the treatment of ovarian cancer and other tumors.

    Read more

  • Moving Continues Driving Big Home Upgrade Decisions

    Homeowners planning to move are far more likely to renovate, particularly for larger, higher-value projects.

    Read more

  • William Blair Recognized Among Massachusetts’ Most Charitable Companies for Sixth Consecutive Year

    William Blair has once again been named one of Massachusetts’ Most Charitable Companies by the Boston Business Journal, marking the sixth consecutive year the firm has received its Corporate Citizenship Award.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures